Revance Therapeutics (NASDAQ:RVNC) Price Target Cut to $20.00 by Analysts at Needham & Company LLC

Revance Therapeutics (NASDAQ:RVNC – Free Report) had its target price trimmed by Needham & Company LLC from $25.00 to $20.00 in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. RVNC has been the topic of a number of other reports. StockNews.com started […]

Related Keywords

United States , ,Revance Therapeutics Inc ,Sg Americas Securities ,Goldman Sachs Group ,Barclays ,Morgan Stanley ,Vanguard Group Inc ,Daymark Wealth Partners ,Revance Therapeutics Company Profile ,Harbor Capital Advisors Inc ,Needham Company ,Revance Therapeutics ,Free Report ,Moderate Buy ,Get Free Report ,Wealth Partners ,Capital Advisors ,Vanguard Group ,Revance Therapeutics Daily ,Nasdaq Rvnc ,Rvnc ,Medical ,Lower Price Target ,Needham Company Llc ,